Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Sara Lonardi, Fotios Loupakis et al.|The Lancet Oncology|2020Cited by 322
Author Index Vol. 77, Suppl. 1, 2009Antônio Rossi, Sabino De Placido, Domenico Galetta et al.|Oncology|2009Cited by 0